Prostaglandin inhibitors and calcium channel blockers were ranked as the top tocolytic therapy options in terms of outcomes of 48-hour delay in delivery, neonatal mortality, respiratory distress syndrome, and maternal side effects, according to a systematic review and network meta-analysis published Oct. 9 in BMJ.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.